Form 4: Kymera CMO Sells Shares Under 10b5-1 Plan

Kymera Therapeutics' Chief Medical Officer, Jared Gollob, executed pre-planned stock option exercises and subsequent share sales.

Summary

• Jared Gollob, Chief Medical Officer of Kymera Therapeutics, Inc. (KYMR), reported transactions on October 13, 2025.
• These transactions were conducted under a Rule 10b5-1 trading plan established on June 2, 2025.
• Gollob exercised stock options to acquire 800 shares of common stock at $1.31 per share.
• He also exercised stock options to acquire 673 shares of common stock at $2.08 per share.
• Following these acquisitions, Gollob sold 3,114 shares of common stock at a price of $60 per share.
• After all reported transactions, Gollob's direct beneficial ownership of common stock is 118,359 shares.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. While there's a sale, it's under a 10b5-1 plan, which mitigates negative sentiment. The exercise of options shows the insider realizing value from their equity compensation.

Positives

• The exercise of stock options indicates the insider is realizing value from previously granted equity compensation.
• Transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests the sales were not based on new, non-public information.

Negatives

• The sale of 3,114 shares by a Chief Medical Officer could be perceived as a slight negative, although mitigated by the 10b5-1 plan.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The filing does not contain direct quotes from management, but notes that the transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2025.

Industry Context

This Form 4 filing reports routine insider transactions and does not provide information directly related to broader industry trends or competitive landscape for Kymera Therapeutics. Such filings are common for executives managing their equity compensation.

Comparison to Industry Standards

• This filing reports standard insider equity transactions. There are no specific company or project results to compare against global benchmarks or competitors. The execution of a 10b5-1 plan is a common practice for executives to manage personal finances and comply with insider trading regulations.

Stakeholder Impact

• Shareholders: May observe a slight increase in shares outstanding due to option exercises, followed by a sale by a key executive. The 10b5-1 plan mitigates concerns about opportunistic selling.

Next Steps

• The filing does not mention any specific future actions, events, or milestones for the company.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions (option exercises and subsequent sales) executed under a pre-arranged 10b5-1 trading plan. Such transactions are generally not indicative of a change in the company's fundamental outlook or a signal for investors to buy or sell based solely on this report. The sale is for personal financial management rather than a reaction to new company-specific information. Therefore, the filing itself does not provide sufficient new information to alter an existing investment thesis, warranting a 'hold' recommendation.

Keywords

Kymera Therapeutics, KYMR, Jared Gollob, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Chief Medical Officer